Lilly
3Q Revenues: $5.7 billion (+5%)
3Q Earnings: $1.2 billion (-4%)  
YTD Revenues: $17.0 billion (+6%)
YTD Earnings: $4.1 billion (+14%)
Comments: Key growth products launched since 2014, consisting of Taltz, Trulicity, Verzenio, Jardiance, Olumiant, Emgality, Tyvyt, Baqsimi, Cyramza, Retevmo and Basaglar contributed nearly 9 percentage points of revenue growth and represented approximately 52% of total revenue for the quarter. Talz sales were $454.5 million, up 34%. Trulicity sales were up 9% to $1.1 billion. Verzenio sales were up 49% to $234.4 million. Jardiance sales were $310.8 million, up 29%. Olumiant sales were up 41% to $162 million. Cyramza sales were up 5% to $252.7 million. Forteo sales declined 28% to $266.9 million. Revenue in the U.S. increased 3% to $3.2 billion, driven by a 7 percent increase in volume, partially offset by a 4 percent decrease due to lower realized prices. Revenue outside the U.S. increased 7% to $2.6 billion, driven by a 12 percent increase in volume and a 1 percent increase due to the favorable impact of foreign exchange rates, partially offset by a 7 percent decrease due to lower realized prices. In the quarter, Lilly submitted an initial request to the U.S. FDA for Emergency Use Authorization for bamlanivimab (LY-CoV555) monotherapy in higher-risk patients who have been recently diagnosed with mild-to-moderate COVID-19.